| Bioactivity | Urabrelimab (SRF231) is a fully human anti-CD47 monoclonal antibody that blocks the CD47-SIRP interaction[1]. |
| Invitro | Urabrelimab (SRF231) 在体外促进巨噬细胞介导的对几种血液原发肿瘤样本和细胞系的吞噬清除。Urabrelimab 增加 Raji 肿瘤细胞系靶细胞的吞噬作用，EC50 为 ~300 ng/mL[1]。 |
| In Vivo | Urabrelimab (SRF231) 在多发性骨髓瘤、弥漫性大 B 细胞淋巴瘤和伯基特淋巴瘤模型中作为单一药物和与调理抗体联合使用可导致显著的肿瘤生长抑制。在 Raji 异种移植模型中，单药治疗可抑制 112% 的肿瘤生长[1]。 |
| Name | Urabrelimab |
| CAS | 2249722-58-3 |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Holland P M, et al. CD47 monoclonal antibody SRF231 is a potent inducer of macrophage-mediated tumor cell phagocytosis and reduces tumor burden in murine models of hematologic malignancies. 2016. |